OTCMKTS:BCDA - BioCardia Stock Price, News & Analysis

$4.99
+0.14 (+2.89 %)
(As of 08/23/2019 07:49 AM ET)
Today's Range
$4.78
Now: $4.99
$5.00
50-Day Range
$4.50
MA: $8.15
$17.50
52-Week Range
$4.32
Now: $4.99
$32.22
Volume35,535 shs
Average Volume3,806 shs
Market Capitalization$33.56 million
P/E RatioN/A
Dividend YieldN/A
Beta1.97
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BCDA
CUSIPN/A
Phone650-226-0120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$630,000.00
Book Value$0.78 per share

Profitability

Net Income$-13,990,000.00
Net Margins-2,191.28%

Miscellaneous

Employees27
Market Cap$33.56 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.


BioCardia (OTCMKTS:BCDA) Frequently Asked Questions

What is BioCardia's stock symbol?

BioCardia trades on the OTCMKTS under the ticker symbol "BCDA."

How were BioCardia's earnings last quarter?

BioCardia Inc (OTCMKTS:BCDA) announced its quarterly earnings results on Thursday, August, 9th. The company reported ($0.08) earnings per share (EPS) for the quarter. The company earned $0.24 million during the quarter. BioCardia had a negative net margin of 2,191.28% and a negative return on equity of 423.10%. View BioCardia's Earnings History.

Has BioCardia been receiving favorable news coverage?

News articles about BCDA stock have been trending positive recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioCardia earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the near term. View News Stories for BioCardia.

Who are some of BioCardia's key competitors?

What other stocks do shareholders of BioCardia own?

Who are BioCardia's key executives?

BioCardia's management team includes the folowing people:
  • Dr. Peter A. Altman, CEO, Pres & Director (Age 52)
  • Dr. Eric Henricus J. Duckers, Chief Medical Officer (Age 51)
  • Mr. David McClung, VP of Fin. (Age 56)
  • Mr. Phil Pesta, VP of Operations (Age 53)
  • Dr. Ian McNiece Ph.D., Chief Scientific Officer (Age 65)

How do I buy shares of BioCardia?

Shares of BCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioCardia's stock price today?

One share of BCDA stock can currently be purchased for approximately $4.99.

How big of a company is BioCardia?

BioCardia has a market capitalization of $33.56 million and generates $630,000.00 in revenue each year. BioCardia employs 27 workers across the globe.View Additional Information About BioCardia.

What is BioCardia's official website?

The official website for BioCardia is http://www.biocardia.com/.

How can I contact BioCardia?

BioCardia's mailing address is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. The company can be reached via phone at 650-226-0120 or via email at [email protected]


MarketBeat Community Rating for BioCardia (OTCMKTS BCDA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  86
MarketBeat's community ratings are surveys of what our community members think about BioCardia and other stocks. Vote "Outperform" if you believe BCDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel